Home > Press > Mapping Tumor Heterogeneity With Quantum Dots
 |
Abstract:
One important discovery made about cancer over the past decade is that as a tumor develops, the molecular identity of its cells begins to diverge. As a result, any given tumor is likely to contain groups of cells with differing genetic makeup, growth rates, and more importantly, susceptibility to specific drug therapies. Now, using a mixture of four quantum dots linked to antibodies that can detect cancer-associated proteins, a research team from Emory University has developed a method for mapping the molecular heterogeneity of human prostate tumor biopsies obtained from cancer patients. This method should be applicable to other types of tumors.
Mapping Tumor Heterogeneity With Quantum Dots
Bethesda, MD | Posted on May 22nd, 2010Shuming Nie, the principal investigator of the Emory University and Georgia Institute of Technology Center of Cancer Nanotechnology Excellence, led the research team that developed this new method of characterizing tumor biopsies. The investigators reported their work in the journal ACS Nano.
Dr. Nie and his team chose four proteins to target using monoclonal antibodies. To each antibody, they linked a quantum dot—a brightly fluorescent nanoparticle—that emits light with a unique optical signature. After staining human prostate cancer with the four antibody-quantum dot constructs, the researchers used a commercial multispectral imaging system to acquire fluorescence images of the tissue. They then analyzed the raw spectral data with a computer algorithm capable of sorting out the four optical signatures and creating a map of the locations where each of the four quantum dots accumulated on the tumor samples. These maps revealed complex microenvironments within tumors and identified major differences across biopsies from multiple patients.
These maps also pinpointed areas of the prostate gland undergoing structural changes characteristic of healthy tissue becoming malignant. In fact, the investigators note that their work shows that the architectural changes that occur in prostate cancer likely start with a single malignant cell in regions of the prostate gland known as the luminal and basal layers.
This work, which is detailed in a paper titled, "Molecular Mapping of Tumor Heterogeneity on Clinical Tissue Specimens with Multiplexed Quantum Dots," was supported in part by the NCI Alliance for Nanotechnology in Cancer, a comprehensive initiative designed to accelerate the application of nanotechnology to the prevention, diagnosis, and treatment of cancer. An abstract of this paper is available at the journal's Web site.
####
About NCI Alliance for Nanotechnology in Cancer
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.
The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.
Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.
For more information, please click here
Copyright © NCI Alliance for Nanotechnology in Cancer
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
| Related News Press |
News and information
Rice U. chemists create 3-D printed graphene foam June 22nd, 2017
Tiny bubbles provide tremendous propulsion in new microparticles research-Ben-Gurion U. June 21st, 2017
Enhanced photocatalytic activity by Cu2O nanoparticles integrated H2Ti3O7 nanotubes June 21st, 2017
Possible Futures
Rice U. chemists create 3-D printed graphene foam June 22nd, 2017
Tiny bubbles provide tremendous propulsion in new microparticles research-Ben-Gurion U. June 21st, 2017
Researchers developed nanoparticle based contrast agent for dual modal imaging of cancer June 21st, 2017
Academic/Education
Oxford Instruments congratulates Lancaster University for inaugurating the IsoLab, built for studying quantum systems June 20th, 2017
The 2017 Winners for Generation Nano June 8th, 2017
MIT Energy Initiative awards 10 seed fund grants for early-stage energy research May 4th, 2017
Bar-Ilan University to set up quantum research center May 1st, 2017
Nanomedicine
Researchers developed nanoparticle based contrast agent for dual modal imaging of cancer June 21st, 2017
Learning with light: New system allows optical “deep learning”: Neural networks could be implemented more quickly using new photonic technology June 12th, 2017
Mussels add muscle to biocompatible fibers: Rice University chemists develop hydrogel strings using compound found in sea creatures June 9th, 2017
Announcements
Rice U. chemists create 3-D printed graphene foam June 22nd, 2017
Tiny bubbles provide tremendous propulsion in new microparticles research-Ben-Gurion U. June 21st, 2017
Enhanced photocatalytic activity by Cu2O nanoparticles integrated H2Ti3O7 nanotubes June 21st, 2017
Quantum Dots/Rods
Graphene and quantum dots put in motion a CMOS-integrated camera that can see the invisible May 29th, 2017
Nanoparticles open new window for biological imaging: “Quantum dots” that emit infrared light enable highly detailed images of internal body structures April 10th, 2017
Particle Works creates range of high performance quantum dots February 23rd, 2017
Nanobiotechnology
Researchers developed nanoparticle based contrast agent for dual modal imaging of cancer June 21st, 2017
Mussels add muscle to biocompatible fibers: Rice University chemists develop hydrogel strings using compound found in sea creatures June 9th, 2017
Nanobiotix's promising data from Phase I/II head and neck cancer trial presented at ASCO June 5th, 2017
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
University Technology Transfer & Patents
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||